SCHEMBL17534150

SCHEMBL17534150

CCCOc1cccc(O)c1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.47
MAPT P10636 3/20 0.47
GAA P10253 2/20 0.47
JAK2 O60674 1/20 0.47
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
TSHR P16473 2/20 0.42
MCHR1 Q99705 1/20 0.41
PTPN1 P18031 1/20 0.41
TP53 P04637 2/20 0.41
CYP3A4 P08684 2/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2C19 P33261 2/20 0.41
CYP2D6 P10635 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CYP2A6 P11509 1/20 0.41
CSNK2A1 P68400 2/20 0.40
ALDH1A1 P00352 4/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20339408 0.88 LMNA (0.49) LMNAMAPTGAAJAK2MCHR1
SCHEMBL9697377 0.88 LMNA (0.49) LMNAMAPTGAAJAK2MCHR1
SCHEMBL3787607 0.86 MCHR1 (0.47) LMNAMAPTGAANPC1RAB9A
SCHEMBL1066091 0.85 TSHR (0.45) LMNAMAPTGAAJAK2NPC1
Methyl Alcohol SCHEMBL11789519 0.83 TSHR (0.43) LMNAMAPTGAAJAK2NPC1
SCHEMBL1052278 0.82 LMNA (0.54) LMNAMAPTGAAJAK2MCHR1
SCHEMBL15473216 0.81 ALDH1A1 (0.54) GAANPC1RAB9ATSHRMCHR1
1-Hydroxy-2-Propoxybenzene SCHEMBL1805086 0.80 GAA (0.72) LMNAMAPTGAAJAK2NPC1
SCHEMBL16957909 0.79 HTR1B (0.43) LMNAMAPTGAANPC1RAB9A
SCHEMBL1837129 0.79 LMNA (0.49) LMNAMAPTGAAJAK2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160060260-A1 BROMODOMAIN INHIBITORS FOR TREATING DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2016-03-03 US disclosed
US-20160060260-A1 BROMODOMAIN INHIBITORS FOR TREATING DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2016-03-03 US disclosed
US-20160060260-A1 BROMODOMAIN INHIBITORS FOR TREATING DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2016-03-03 US disclosed
WO-2016033416-A1 BROMODOMAIN INHIBITORS FOR TREATING DISEASE BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) 2016-03-03 WO disclosed
WO-2016033416-A1 BROMODOMAIN INHIBITORS FOR TREATING DISEASE BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) 2016-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160060260-A1 BROMODOMAIN INHIBITORS FOR TREATING DISEASE BRDT, BRPF3, BRWD1 LMNA 2533/4885MAPT 1371/4885GAA 1704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.